Deepu Madduri - Concepedia

Author

Deepu Madduri

Icahn School of Medicine at Mount Sinai ORCID

Also Known As

D Madduri, D. Madduri, Deepu Madduri, Madduri, Deepu

162

Publications

12.1K

Citations

H-Index

Concepts

All Affiliations

Icahn School of Medicine at Mount Sinai Sarah Cannon Janssen (United States)Mount Sinai Medical Center University of Chicago

About

Deepu Madduri is an author at Icahn School of Medicine at Mount Sinai specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	5.1K
2	Health Sciences	11	11	2K
3	Cellular Therapies	5	5	1.7K
4	Public Health	2	2	113
5	Engineering	1	1	37

Deepu Madduri

Publications

11.5K

Citations

H-Index

Page 1

	Year	Citations
An inflammatory cytokine signature predicts COVID-19 severity and survival Diane M. Del Valle, Seunghee Kim‐Schulze, Hsin-Hui Huang, Nature Medicine InflammationCovid-19 PandemicImmunologyInflammatory Cytokine SignatureInflammatory Marker	2020	2.6K
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Nikhil C. Munshi, Larry D. Anderson, Nina Shah, New England Journal of Medicine	2021	2.3K
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma Noopur Raje, Jesús G. Berdeja, Yi Lin, New England Journal of Medicine	2019	1.7K
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, The Lancet Hematological MalignancyCell TherapyImmunotherapyCiltacabtagene AutoleucelMedicine	2021	1.5K
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up Thomas G. Martin, Saad Z. Usmani, Jesús G. Berdeja, Journal of Clinical Oncology	2022	580
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies Adam D. Cohen, Samir Parekh, Bianca Santomasso, Blood Cancer Journal	2022	235
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy Oliver Van Oekelen, Adolfo Aleman, Bhaskar Upadhyaya, Nature Medicine Corticobasal DegenerationMedicineParkinson DiseaseHypokinetic Movement DisorderNeurological Disorder	2021	228
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward Bo Wang, Oliver Van Oekelen, Tarek H. Mouhieddine, Journal of Hematology & Oncology	2020	141
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM) Deepu Madduri, Saad Z. Usmani, Sundar Jagannath, Blood	2019	119
A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM) Simon J. Harrison, Monique C. Minnema, Hans C. Lee, Blood	2020	112

Page 1